Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page has a new site revision (v3.4.2) and several navigation/operational notices were removed, affecting metadata and links without altering study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check21 days agoChange DetectedA government funding notice about potential delays and a page revision from v3.4.0 to v3.4.1 were added. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdditions include a glossary toggle, Last Update Submitted that Met QC Criteria, Last Update Posted, a No FEAR Act Data disclosure, and Revision: v3.4.0. Deletions remove Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedA new page revision, v3.3.4, was added and the previous revision, v3.3.3, was removed.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Florida location under Locations and updated the page revision to v3.3.3. Removed the older Florida Locations entry and the HHS Vulnerability Disclosure link.SummaryDifference0.4%

- Check91 days agoChange DetectedRevision metadata updated from v3.2.0 to v3.3.2; no user-facing content changes observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.